Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in bone marrow transplantation.

S Slavin1, A Nagler

  • 1Department of Surgery, Hadassah University Hospital, Jerusalem, Israel.

Current Opinion in Oncology
|April 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Bone marrow transplantation·2026
Same author

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study.

Bone marrow transplantation·2021
Same author

Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT.

Bone marrow transplantation·2020
Same author

Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria).

Bone marrow transplantation·2020
Same author

Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2019
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Immunotherapy using cytokines like recombinant human interleukin-2 and interferon-alpha shows promise in controlling minimal residual disease after bone marrow transplantation. This approach may lead to safer applications and better outcomes in cancer treatment.

Area of Science:

  • Immunology
  • Oncology
  • Hematology

Background:

  • Bone marrow transplantation (BMT) is a critical cancer treatment, but residual tumor cells pose a significant challenge.
  • Understanding post-transplant immunobiology and recombinant cytokines is crucial for safer BMT applications.

Purpose of the Study:

  • To explore innovative immunotherapies for controlling minimal residual disease (MRD) after BMT.
  • To evaluate the efficacy of recombinant cytokines and adoptive immunotherapy in enhancing anti-leukemia effects.

Main Methods:

  • Administration of recombinant human interleukin-2 (IL-2) and interferon-alpha (IFN-α) in animal models.
  • Induction of graft-versus-leukemia (GvL) effects using allogeneic lymphocytes and IL-2 post-BMT.

Main Results:

Related Experiment Videos

  • Cytokine therapy demonstrated control of minimal residual disease in preclinical models.
  • Combined immunotherapy with lymphocytes and IL-2 induced significant GvL effects, showing promise in human trials.

Conclusions:

  • Complete eradication of all tumor cells may not be necessary for successful cancer treatment.
  • Activating anticancer effector cells via immunotherapy offers a viable strategy for controlling MRD and improving clinical outcomes in the near future.